ClinicalTrials.gg
RecruitingNCT02476786Updated Jul 27, 2026

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

A Phase 2 interventional study of FACT-B and Goserelin in Breast Cancer, Cancer of Breast and Breast Neoplasms, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to female participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment

How we know · 11 judgments

From the registry’s dates

  • Started Jan 2017; still recruiting 9 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
70 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies testing goserelin in Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Goserelin · Breast Neoplasms.

Planned enrollment
33rd of 41
50 · median 147
Started
2017
with 1 other
Phase 2
21 of 43
6 open now
Registered
27th of 43
by date
Lead sponsor
2 of 43
Washington University School of Medicine

Among the 43 studies testing goserelin in Breast Neoplasms, this one is the 33rd largest by planned enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2017, is one of 21 in phase 2, and was the 27th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 43 studies testing goserelin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About goserelin

Goserelin: first FDA approval 1989 (ZOLADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 70 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing goserelin in Breast Neoplasms, or all of them as a file.
02

Study summary

Multiple neoadjuvant endocrine trials demonstrate that women with good prognosis tumors can be identified. These trials have also demonstrated that there are not adverse effects on overall outcome if women are treated with neoadjuvant endocrine therapy for several months prior to definitive treatment. A new standard of care needs to be defined for elderly women with good prognosis estrogen receptor (ER)+ tumors, since these women may benefit from endocrine therapy alone to treat their cancer without compromising local and distant control. The investigators hypothesize that endocrine therapy alone provides adequate local and systemic control of breast cancer in a subpopulation of women 70 or older with ER+ breast cancer and low Ki67 scores.

03

Conditions studied

  • Breast Cancer
  • Cancer of Breast
  • Breast Neoplasms
  • Cancer of the Breast

Browse trials for

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed or cytologically confirmed operable invasive breast cancer defined as cT1 or T2, N0-1, and M0.
  • Disease must be ER+ and -.
  • Ki67 score/proliferative index ≤ 30% or low to intermediate mitotic index
  • defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) by ultrasound or mammogram.
  • 70 years of age or older.
  • performance status ≤ 3
  • Able to understand and willing to sign an IRB approved written document (or that of legally authorized representative, if applicable).

Exclusion criteria

Exclusion Criteria:

  • Prior surgery for this cancer
  • A history of other ≤ 5 years previous which would preclude endocrine treatment of their cancer.
  • Currently receiving any other agents.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the study.
  • Uncontrolled intercurrent illness as determined by their treating physician which would limit compliance with study requirements.
  • Known -positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with endocrine therapies. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Endocrine therapy alone

    * Neoadjuvant endocrine therapy will be given at the discretion of the treating physician as directed by the package insert and could include the following: goserelin, anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen * Frequency of office visits will be decided by the treating physician but must occur no less frequently than every 3 to 6 months for tumor assessment * After 6 months and after 12 months, patients will be assessed; patients who progress will have standard care recommended , and at any point a patient can opt to receive standard care even if she has not progressed on neoadjuvant endocrine therapy * Information on quality of life will be collected at baseline, Year 1, and Year 2 by the FACT-B questionnaire * Archival tissue will be collected and sent to Genomic Health for analysis using the Oncotype DX assay. The Recurrence Score predicts chemotherapy benefit and indicates the 10-year risk of recurrence (will not be used to determine treatment)

    Behavioral: FACT-B · Drug: Goserelin · Drug: Anastrozole · Drug: Exemestane · Drug: Fulvestrant · Drug: Tamoxifen · Other: Archived tissue collection

Interventions

  • BehavioralFACT-B

    The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).

  • Also known as: Goserelin acetate, Zoladex

  • Also known as: Arimidex®

  • Also known as: Aromasin®

  • Also known as: Faslodex®

  • Also known as: Nolvadex®

  • OtherArchived tissue collection
06

What researchers measure

Primary outcomes

  1. Response rate

    * Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) \[Eur J Ca 45:228-247, 2009\]. * In each RECIST response category Oncotype DX scores will be summarized with mean, standard deviation, minimum, 1st, 2nd (median) and 3rd quartiles, and maximum values. OncotypeDx scores range from 0 to 100, with scores \<18 indicating low risk.

    Time frame: 6 months

Secondary outcomes

  1. Breast cancer-specific survival

    Time frame: 6 months

  2. Breast cancer-specific survival

    Time frame: 1 year

  3. Breast cancer-specific survival

    Time frame: 2 years

  4. Rate of overall survival

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Rebecca L Aft, M.D., Ph.D. · Contactaftr@wustl.edu · 314-747-0063
    • Tracey Guthrie · Contactguthriet@wustl.edu · 314-747-4404
    • Rebecca L Aft, M.D., Ph.D. · Principal investigator
    • Foluso Ademuyiwa, M.D. · Sub investigator
    • Ron Bose, M.D., Ph.D. · Sub investigator
    • Andrew Davis, M.D. · Sub investigator
    • William Gillanders, M.D. · Sub investigator
    • Cynthia X Ma, M.D., Ph.D. · Sub investigator
    • Julie Margenthaler, M.D. · Sub investigator
    • Rama Suresh, M.D. · Sub investigator
    • Katherine N Weilbaecher, M.D. · Sub investigator
    • Ashley Frith, M.D. · Sub investigator
    • Peter Oppelt, M.D. · Sub investigator
    • Antonella Rastelli, M.D. · Sub investigator
    • Caron Rigden, M.D. · Sub investigator
    • Lindsay Peterson, M.D. · Sub investigator
    • Fei Wan, Ph.D. · Sub investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2017 (actual). Primary completion is estimated for Jan 2027, 120 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 120 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2015
First posted
Jun 19, 2015
StartActual
Jan 17, 2017
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jul 31, 2032
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02476786
Responsible party
Sponsor
First posted
Jun 19, 2015
Start date
Jan 17, 2017
Primary completion
Jan 31, 2027 (estimated)
Completion
Jul 31, 2032 (estimated)
Last update
Jul 27, 2026

Study contacts

Rebecca L Aft, M.D., Ph.D.
Contact
aftr@wustl.edu
314-747-0063
Tracie Guthrie
Contact
guthriet@wustl.edu
314-747-4404
Rebecca L Aft, M.D, Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Goserelin · Anastrozole · Exemestane · Tamoxifen

Start the discussion